Boston Scientific Corporation (NYSE:BSX) executive Thepaut Eric Francis Yves, who serves as the EVP & President of Europe, Middle East, and Africa, has recently engaged in transactions involving the company's stock, according to the latest filings. On May 10, Thepaut sold 12,931 shares of common stock at prices ranging from $74.13 to $74.165, with the total sale amounting to over $958,717.
The transactions also included the acquisition of the same number of shares through the exercise of stock options at a price of $16.31 per share, totaling $210,904. These exercised options are part of a grant that allows Thepaut to purchase shares that vest in four equal annual installments, beginning from the first anniversary of the grant date on February 23, 2016.
Following these transactions, Thepaut's direct ownership in Boston Scientific common stock has been adjusted to 31,421.99 shares. The sales were executed as part of a prearranged trading plan, and the details of the transactions have been fully disclosed, with the promise to provide further information on the breakdown of sales prices upon request.
Investors often monitor insider transactions such as these for insights into executive confidence and company performance. Boston Scientific, headquartered in Marlborough, Massachusetts, specializes in the manufacturing of medical devices used in interventional medical specialties.
For those interested in the specifics of the transactions, the weighted average sale price for the shares sold was $74.141. The reporting person has agreed to provide additional details regarding the number of shares sold at each separate price if requested by the SEC, the issuer, or a security holder of the issuer.
The recent activity in Boston Scientific stock by a high-level executive is noteworthy information for investors and market watchers, reflecting the ongoing financial decisions made by company insiders.
InvestingPro Insights
Boston Scientific Corporation (NYSE:BSX) has been in the spotlight with recent insider transactions, and a closer look at the company through InvestingPro metrics and tips offers a broader view of its financial health and market performance. With a robust market capitalization of $107.04 billion and a P/E ratio that stands at 60.24, the company's valuation reflects significant investor confidence. Adjusted data from the last twelve months as of Q1 2024 shows a P/E ratio of 58.44, which, when paired with a PEG ratio of 0.6, suggests that Boston Scientific is trading at a low price-to-earnings ratio relative to its earnings growth.
InvestingPro Tips highlight that Boston Scientific is expected to see net income growth this year, with 19 analysts having revised their earnings estimates upwards for the upcoming period. This positive sentiment is compounded by the fact that the company is a prominent player in the Healthcare Equipment & Supplies industry, which can be a reassuring factor for investors considering the stock's potential. Moreover, the company has demonstrated a strong performance over the last six months, with a price total return of 37.2%.
For investors looking for more detailed analysis and additional insights, there are over 17 InvestingPro Tips available for Boston Scientific at InvestingPro. These tips can provide a deeper understanding of the company's financial position and market performance. To access these insights and enhance your investment strategy, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.